| Nov 13 |
Mineralys Therapeutics Announces Q3 2024 Results and Updates
|
| Nov 12 |
Q3 2024 Mineralys Therapeutics Inc Earnings Call
|
| Nov 12 |
Mineralys Therapeutics, Inc. (MLYS) Q3 2024 Earnings Call Transcript
|
| Nov 11 |
Mineralys Therapeutics GAAP EPS of -$1.13 misses by $0.31
|
| Nov 11 |
Mineralys Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
|
| Nov 11 |
Earnings Scheduled For November 11, 2024
|
| Nov 5 |
Mineralys Therapeutics to Participate in Upcoming Investor Conferences
|
| Nov 4 |
Mineralys Therapeutics to Announce Third Quarter 2024 Financial Results and Host Conference Call on Monday, November 11, 2024
|
| Oct 30 |
Mineralys Therapeutics Completes Enrollment Ahead of Schedule in Launch-HTN, the Second Pivotal Trial of Lorundrostat for the Treatment of Hypertension
|
| Oct 22 |
Mineralys to Host Virtual KOL Event on the Unmet Medical Need in Uncontrolled and Resistant Hypertension, and Lorundrostat as a Potential Treatment on October 30, 2024
|
